Factor V Leiden mutation as a risk factor for recurrent pregnancy loss

Annals of Internal Medicine

Volumn 128, Issue 12 PART 1, 1998, Pages 1000-1003

  Ridker, Paul M ^d   Miletich, Joseph P ^c   Buring, Julie E ^d   Ariyo, Abraham A ^b   Price, Daniel T ^a   Manson, JoAnn E ^d   Hill, Joseph A ^d  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTEIN C;

ARTICLE; CONTROLLED STUDY; FEMALE; FETUS DEATH; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MUTATION RATE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; THROMBOSIS;

EID: 0032525869     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-12_part_1-199806150-00007     Document Type: Article

References (23)

1. Hill JA. Sporadic and recurrent spontaneous abortion. Current Problems in Obstetrics, Gynecology, and Fertility. 1994;4:116-62.
2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-8.
3. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbrouke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-6.
4. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994; 343:1536-8.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
6. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-22.
7. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
8. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.
9. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism. Circulation. 1997;95:1777-82.
10. Vandenbrouke JP, Koster T, Briet E, Reitsma PH, Bertina R, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-7.
11. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hen-nekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997; 126:528-31.
12. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127:895-903.
13. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996; 348:913-6.
14. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 1996; 92:489-90.
15. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725-7.
16. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277:1305-7.
17. Buring JE, Hennekens CH. The Women's Health Study: summary of the study design. Women's Health Study Research Group. J Myocard Ischemia. 1992;4:27-9.
18. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996;131:1145-8.
19. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-3.
20. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol. 1997;176:883-6.
21. Grisaru D, Fait G, Eldor A. Activated protein C resistance and pregnancy complications [Letter]. Am J Obstet Gynecol. 1996;174:801-2.
22. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997;97:551-4.
23. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997;77:822-4.